Potassium Dichromate

Summary

Potassium Dichromate (CHEMBL1374101) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1374101
Name	Potassium Dichromate
Type	Small molecule
Max phase	3

Also known as: NSC-77372, Potassium dichromate, Potassium dichromate(vi), SID17388763, potassium dichromate, SID144204560, SID144209505, POTASSIUM DICHROMATE

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, ATP-dependent DNA helicase Q1, Thyroid hormone receptor beta, Thyrotropin receptor, Cellular tumor antigen p53, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 7 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TP53	5	Potency	10000	nM	CHEMBL_ACT_4854105

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).